NCT03090035View on ClinicalTrials.gov

Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

July 1, 2014

Study Completion Date

December 31, 2014

Conditions
Hepatitis CHepatitis C Relapse
Interventions
DRUG

Pegylated Interferon α2

Peg-INF was given in a dose of 180 μg/week

DRUG

Ribavirin

ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3

Trial Locations (1)

64200

Muhammad Zafar Majeed Babar, Sadiqabad

All Listed Sponsors
lead

Sheikh Zayed Medical College

OTHER_GOV

NCT03090035 - Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment | Biotech Hunter | Biotech Hunter